Neurol. praxi. 2017;18(4):253-255 | DOI: 10.36290/neu.2017.094
PEGylated interferon beta-1a: a novel interferon in treating multiple sclerosis
- Neurologická klinika FN Ostrava
Another drug for relapsing-remitting multiple sclerosis (MS) has been introduced into the market in recent months. It is the socalled“PEGylated” interferon beta-1a. It is the original interferon beta-1a molecule, which has been known in the treatment of MSfor two decades, but has newly been bound to a molecule of polyethylene glycol (PEG), which provides it with some propertiesimproving the overall profile of the original interferon molecule. The article summarizes the profile of efficacy on clinical andradiological parameters and the safety profile of the drug established by the pivotal clinical trial ADVANCE as well as by its extensionstudy, called ATTAIN. PEGylated interferon beta-1a has now expanded the portfolio of first-line disease-modifying drugs(DMDs) used in the treatment of clinically isolated syndrome or relapsing-remitting MS.
Keywords: interferon beta-1a, pegylation, relapse, disability, MRI, NEDA concept
Published: October 1, 2017 Show citation
References
- Arnold DL, Calabresi PA, Kieseier BC, Liu S, You X, Fiore D, Hung S. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. BMC Neurol 2017 Feb 10; 17(1): 29.
Go to original source... - Arnold DL, Shang S, Castrillo-Viguera C, Fiore D. Peginterferon Beta-1a every 2 weeks increased achievement of NEDA over 4 years in the ADVANCE and ATTAIN studies in patients with RRMS. ECTRIMS, 14.-17. Září 2016, London, UK. P1171.
- Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A for the ADVANCE study investigators. Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13(7): 657-665. Go to original source...
Go to PubMed... - Fiore D, Hung S, Tang W, Cui Y, You X, Shang S, Scott T. ADVANCE phase 3 extension study (ATTAIN): peginterferon Beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years. 68th Annual Meeting of the American Academy of Neurology, 15.-21. dubna 2016 Vancouver, Kanada. P4.010.
- Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97(10): 4167-4183. Go to original source... Go to PubMed...
- Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3): 214-221. Go to original source... Go to PubMed...
- Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009; 14(2): 363-380. Go to original source...
- Keiseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015; 21(8): 1025-1035. Go to original source... Go to PubMed...
- Newsome SD, Kieseier BC, Liu S, You X, Kinter E, Hung S, Sperling B. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE. Ther Adv Neurol Disord 2017; 10 (1): 41-50. Go to original source... Go to PubMed...